about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Catch­ing up with Mer­ck in ad­ju­vant melanoma, Bris­tol My­ers bur­nish­es Op­di­vo pro­file in ear­li­er stages of can­cer

3 years ago
R&D
Pharma

That $930M drug Alex­ion bought to pair with Soliris, Ul­tomiris? As­traZeneca says it just aced a PhI­II test

3 years ago
R&D

Up­dat­ed: Striv­ing for 2023 launch, Pfiz­er touts topline PhI­II win for an­oth­er mass mar­ket vac­cine

3 years ago
R&D

First of more? Third Har­mon­ic prices up­sized IPO to raise $185M

3 years ago
Financing

Swiss reg­u­la­tors in­ves­ti­gate No­var­tis over 'un­law­ful abuse' of der­ma­tol­ogy patent

3 years ago
Pharma
Law

CSL takes the wraps off a big new R&D cen­ter as it eyes vac­cines, cell and gene ther­a­pies

3 years ago
R&D
Pharma

Ru­bius re­sorts to lay­offs and aban­dons its lead pro­grams as its sur­vival strat­e­gy

3 years ago
People
R&D

With fresh $160M, Rayze­Bio plots sprint through the clin­ic for lead ra­dio­phar­ma­ceu­ti­cal pro­gram — build­ing on ...

3 years ago
Financing

In af­ter­math of lead drug im­plo­sion, Ob­sE­va's re­struc­tur­ing claims 70% of its staffers — reach­ing in­to the C-suite

3 years ago
People

The sci­en­tist who pi­o­neered KRAS drugs has a new idea about mak­ing them more pow­er­ful

3 years ago
Startups
Discovery

In the mid­dle of an R&D shake­up, No­var­tis makes a $300M in­vest­ment in ear­ly-stage bi­o­log­ics re­search tech

3 years ago
Pharma
Manufacturing

Bris­tol My­ers Squibb scores TYK2 OK; ARCH backs mR­NA plat­form play; Il­lu­mi­na’s $8B co­nun­drum; Siz­ing up Al­ny­lam's ...

3 years ago
Weekly

Bris­tol My­ers wins a megablock­buster bet with TYK2 FDA ap­proval — and there's a big bonus for the la­bel

3 years ago
R&D

'The ur­gency is in­creas­ing': Mod­er­na spot­lights vac­cine, or­phan drug pro­grams, as it plots growth be­yond Covid

3 years ago
R&D

With first drug on the mar­ket, Ar­cutis forks over $16M cash for a buy­out

3 years ago
Deals

#ES­MO22: Bris­tol My­ers spells out kid­ney can­cer flop for Op­di­vo/Yer­voy com­bo — but can a triplet catch on?

3 years ago
R&D

Watch out Mod­er­na: John Maraganore, ARCH and Beam are hatch­ing a plat­form play 'to lead the fu­ture of RNA ther­a­pies'

3 years ago
Startups
Cell/Gene Tx

On fi­nal dash to the clin­ic, Ar­se­nal­Bio hauls in $220M for 'mod­u­lar' cell ther­a­py ap­proach

3 years ago
Financing
Cell/Gene Tx

Seek­ing first-in-class glo­ry, Roche en­lists biotech part­ner that prides it­self on crack­ing 'un­drug­gable' tar­gets

3 years ago
Deals

Lat­est news on FDA’s sec­ond look at Amy­lyx; Un­pack­ing Parkin­son’s R&D; Fiona Mar­shall takes over NI­BR from Jay ...

3 years ago
Weekly

Top Boehringer In­gel­heim drug gets FDA ap­proval in rare skin dis­ease

3 years ago
Pharma
FDA+

Pfiz­er reshuf­fles top lead­er­ship to hone com­mer­cial strat­e­gy, leav­ing room for new rare dis­ease chief

3 years ago
People
Pharma

In wake of third straight mid-stage set­back, Anap­tys­Bio looks to punt IL-36 drug — even as PhI­II goes on

3 years ago
R&D

Mor­phoSys woos Mer­ck KGaA vet to lead late-stage push for block­buster prospect

3 years ago
People
First page Previous page 24252627282930 Next page Last page
A service from the Financial Times